Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT

Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT

Background: In chronic central serous chorioretinopathy, fluid accumulates in the subretinal space and causes permanent vision loss in ≈ 30% of patients. There is no definitive treatment. Previous research suggests that the mineralocorticoid receptor antagonist eplerenone is effective but it is not...

Full description

Bibliographic Details
Main Authors: Andrew Lotery, Sobha Sivaprasad, Abby O’Connell, Rosie A Harris, Lucy Culliford, Angela Cree, Savita Madhusudhan, Helen Griffiths, Lucy Ellis, Usha Chakravarthy, Tunde Peto, Chris A Rogers, Barnaby C Reeves
Format: Article
Language:English
Published: NIHR Journals Library 2021-01-01
Series:Efficacy and Mechanism Evaluation
Subjects:
central serous chorioretinopathy
eplerenone
mineralocorticoid receptor antagonist
randomised controlled trial
subretinal fluid
visual acuity
Online Access:https://doi.org/10.3310/eme08020

Internet

https://doi.org/10.3310/eme08020

Similar Items